Assessment of the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients
Abstract Objective. This study was aimed to evaluate the prevalence of Cushing’s syndrome and the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients. Methods. Anthropometric measurements and other laboratory data, including 1 mg dexamethasone suppression test of 753 class 3 obese patients, who applied to the Endocrinology and Metabolism Outpatient Clinic for the pre-bariatric surgery evaluation between 2011 and 2020, were evaluated retrospectively. Results. An abnormal response to the 1 mg dexamethasone suppression test (cortisol ≥1.8 mcg/dl) was observed in 24 patients and the presence of Cushing’s syndrome was confirmed by additional tests in 6 patients. The prevalence of abnormal dexamethasone suppression test was 3.18% and the prevalence of Cushing’s syndrome 0.79%. The specificity value was determined as 97.5% for 1 mg dexamethasone suppression test with cortisol threshold value ≥1.8 mcg/dl. Conclusions. The prevalence of Cushing’s syndrome was found to be low in class 3 obese patients and 1 mg of dexamethasone suppression test had a very sufficient performance for Cushing’s syndrome screening in this patient group..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Endocrine regulations - 56(2022), 4 vom: 01. Okt., Seite 265-270 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baldane, Suleyman [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
© 2022 Suleyman Baldane et al., published by Sciendo |
|---|
| doi: |
10.2478/enr-2022-0028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY008502668 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY008502668 | ||
| 003 | DE-627 | ||
| 005 | 20230813125155.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230813s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2478/enr-2022-0028 |2 doi | |
| 035 | |a (DE-627)GRUY008502668 | ||
| 035 | |a (DE-B1597)enr-2022-0028-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Baldane, Suleyman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 Suleyman Baldane et al., published by Sciendo | ||
| 520 | |a Abstract Objective. This study was aimed to evaluate the prevalence of Cushing’s syndrome and the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients. Methods. Anthropometric measurements and other laboratory data, including 1 mg dexamethasone suppression test of 753 class 3 obese patients, who applied to the Endocrinology and Metabolism Outpatient Clinic for the pre-bariatric surgery evaluation between 2011 and 2020, were evaluated retrospectively. Results. An abnormal response to the 1 mg dexamethasone suppression test (cortisol ≥1.8 mcg/dl) was observed in 24 patients and the presence of Cushing’s syndrome was confirmed by additional tests in 6 patients. The prevalence of abnormal dexamethasone suppression test was 3.18% and the prevalence of Cushing’s syndrome 0.79%. The specificity value was determined as 97.5% for 1 mg dexamethasone suppression test with cortisol threshold value ≥1.8 mcg/dl. Conclusions. The prevalence of Cushing’s syndrome was found to be low in class 3 obese patients and 1 mg of dexamethasone suppression test had a very sufficient performance for Cushing’s syndrome screening in this patient group. | ||
| 700 | 1 | |a Celik, M |4 aut | |
| 700 | 1 | |a Kebapcilar, Levent |4 aut | |
| 700 | 1 | |a Ipekci, Suleyman Hilmi |4 aut | |
| 700 | 1 | |a Abusoglu, Sedat |4 aut | |
| 700 | 1 | |a Yilmaz, Huseyin |4 aut | |
| 700 | 1 | |a Alptekin, Husnu |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine regulations |d Sciendo, 1995 |g 56(2022), 4 vom: 01. Okt., Seite 265-270 |h Online-Ressource |w (DE-627)GRUY000328200 |w (DE-600)2053166-7 |w (DE-576)28120537X |x 1336-0329 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2022 |g number:4 |g day:01 |g month:10 |g pages:265-270 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2478/enr-2022-0028 |z kostenfrei |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2022 |e 4 |b 01 |c 10 |h 265-270 | ||